Aclarion Provides Shareholder Update
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced the submission of an 8-K filing for stakeholder review. The company plans to file its 10-K by the end of March 2025, accompanied by a comprehensive corporate update.
Aclarion (Nasdaq: ACON), un'azienda tecnologica nel settore sanitario specializzata nella diagnosi del dolore cronico alla schiena tramite biomarcatori e algoritmi di intelligenza artificiale, ha annunciato la presentazione di un filing 8-K per la revisione degli stakeholder. L'azienda prevede di presentare il suo 10-K entro la fine di marzo 2025, accompagnato da un aggiornamento aziendale completo.
Aclarion (Nasdaq: ACON), una empresa de tecnología en salud especializada en el diagnóstico del dolor crónico de espalda baja a través de biomarcadores y algoritmos de inteligencia artificial, ha anunciado la presentación de un informe 8-K para la revisión de los interesados. La empresa planea presentar su 10-K antes de finales de marzo de 2025, acompañado de una actualización corporativa integral.
Aclarion (Nasdaq: ACON), 만성 요통 진단을 위한 바이오마커 및 AI 알고리즘을 전문으로 하는 헬스케어 기술 회사는 이해관계자 검토를 위한 8-K 제출을 발표했습니다. 회사는 2025년 3월 말까지 포괄적인 기업 업데이트와 함께 10-K를 제출할 계획입니다.
Aclarion (Nasdaq: ACON), une entreprise de technologie de la santé spécialisée dans le diagnostic de la douleur chronique du bas du dos par le biais de biomarqueurs et d'algorithmes d'IA, a annoncé la soumission d'un dépôt 8-K pour examen par les parties prenantes. L'entreprise prévoit de déposer son 10-K d'ici la fin mars 2025, accompagné d'une mise à jour complète de l'entreprise.
Aclarion (Nasdaq: ACON), ein Technologieunternehmen im Gesundheitswesen, das sich auf die Diagnose von chronischen Rückenschmerzen durch Biomarker und KI-Algorithmen spezialisiert hat, hat die Einreichung eines 8-K-Dokuments zur Überprüfung durch die Stakeholder angekündigt. Das Unternehmen plant, seinen 10-K bis Ende März 2025 einzureichen, begleitet von einem umfassenden Unternehmensupdate.
- None.
- None.
BROOMFIELD, Colo., March 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be viewed here.
The Company intends on filing its 10K by the end of March and plans to provide a more in-depth Corporate Update at that time.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
FAQ
When will Aclarion (ACON) file its 10-K report for 2024?
What regulatory filings has Aclarion (ACON) recently submitted?
What is Aclarion's (ACON) core business technology?
When will Aclarion (ACON) provide its next corporate update?
